Longterm therapy in polymyalgia rheumatica: Effect of coexistent temporal arteritis

Citation
J. Narvaez et al., Longterm therapy in polymyalgia rheumatica: Effect of coexistent temporal arteritis, J RHEUMATOL, 26(9), 1999, pp. 1945-1952
Citations number
36
Categorie Soggetti
Rheumatology,"da verificare
Journal title
JOURNAL OF RHEUMATOLOGY
ISSN journal
0315162X → ACNP
Volume
26
Issue
9
Year of publication
1999
Pages
1945 - 1952
Database
ISI
SICI code
0315-162X(199909)26:9<1945:LTIPRE>2.0.ZU;2-A
Abstract
Objective. To analyze the clinical course and duration of therapy in a seri es of 104 patients with polymyalgia rheumatica (PMR), identifying factors t hat influence prolonged steroid use and relapses. Methods, Retrospective study of 104 cases of PMR diagnosed from 1985 to 199 5. Patients were followed from time of diagnosis until either their death o r December 31, 1995. To assess the effects of the coexistence of temporal a rteritis (TA) on outcome in PMR, patients were grouped according to the abs ence or presence of arteritis. Kaplan-Meier survival analysis was performed to evaluate the duration of therapy, the incidence of prolonged remissions and relapses, and the average time to relapse. The log rank test was used to test for significant differences between groups. Multivariate Cox propor tional hazards regression models were used to identify variables associated with the occurrence of these events. Results. Of 104 patients, 69 had pure PMR and 35 had both PMR and TA. Altho ugh some patients had limited disease requiring limited corticosteroid (CS) therapy (usually about 2 years), a significant number of patients had sust ained disease requiring longterm treatment. Patients with simultaneous arte ritis tended to have a longer duration of therapy, but no increased risk of relapse. By multivariate analysis, increasing age at diagnosis, female sex , higher baseline erythrocyte sedimentation rate, and lower daily CS dose w ere significant risk factors associated with long duration of therapy. No c linical feature predicted patients who were more likely to relapse. Conclusion. Although there was great individual patient variation, we found that typically CS therapy lasted at least 2 years. Our findings allow the identification of patients who are particularly predisposed to need prolong ed and higher dose cumulative steroid therapy and merit preventive strategi es to decrease the incidence of steroid related adverse events.